Pauls Matthew 4
4 · Pelthos Therapeutics Inc. · Filed Jul 7, 2026
Research Summary
AI-generated summary of this filing
Pelthos (PTHS) Director Pauls Matthew Sells 786 Shares
What Happened
Pauls Matthew, a director of Pelthos Therapeutics Inc. (PTHS), sold a total of 786 shares in open-market transactions on July 2, 2026, generating proceeds of approximately $20,561. The sales consisted of 692 shares reported at $26.00 (proceeds $17,989) and 94 shares reported at $27.36 (proceeds $2,572). These were sales (not purchases) and are typically treated as routine dispositions rather than bullish insider buying.
Key Details
- Transaction date: July 2, 2026. Filing date: July 7, 2026.
- Reported share breakdown: 692 shares (reported price $26.00) and 94 shares (reported price $27.36). Total proceeds roughly $20,561.
- Execution details: The 692-share block was executed in multiple trades at prices from $25.58 to $26.24 (weighted average reported). The 94-share block was executed in multiple trades at prices from $27.20 to $27.63 (weighted average reported). The filer offers to provide full trade-by-trade details on request.
- Footnote: The sales were made pursuant to a Rule 10b5-1 trading plan adopted December 16, 2025, to satisfy estimated tax obligations related to vesting restricted stock units.
- Shares owned after the transaction: not provided in the excerpt of the filing.
- Timing note: The Form 4 was filed five days after the transaction (filed 2026-07-07 for a 2026-07-02 trade); Form 4s are generally due within two business days, so this filing appears delayed.
Context
Sales under 10b5-1 plans are common for covering tax obligations tied to equity awards and are typically considered routine rather than a signal of insider sentiment. For retail investors, purchases by insiders usually carry more immediate informational weight than routine sales; this filing documents a tax-related disposition rather than an opportunistic market buy.
Insider Transaction Report
- Sale
Common Stock
[F1][F2]2026-07-02$26.00/sh−692$17,989→ 14,458 total - Sale
Common Stock
[F1][F3]2026-07-02$27.36/sh−94$2,572→ 14,364 total
Footnotes (3)
- [F1]This transaction reflects the sale of shares, made pursuant to a Rule 10b5-1 plan adopted December 16, 2025, for the purpose of satisfying estimated tax obligations in connection with the vesting of restricted stock units granted by the Issuer.
- [F2]This transaction was executed in multiple trades at prices ranging from $25.58 to $26.24. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.
- [F3]This transaction was executed in multiple trades at prices ranging from $27.20 to $27.63. The price reported in column 4 above reflects the weighted average price of the shares of Common Stock sold. The Reporting Person hereby undertakes to provide upon request to the SEC staff, the issuer or a security holder of the issuer full information regarding the number of shares and prices at which the transaction was effected.